Suppr超能文献

NCCN 指南®洞察: Merkel 细胞癌,第 1.2024 版。

NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024.

机构信息

Dana-Farber/Brigham and Women's Cancer Center.

Duke Cancer Institute.

出版信息

J Natl Compr Canc Netw. 2024 Jan;22(1D):e240002. doi: 10.6004/jnccn.2024.0002.

Abstract

The NCCN Guidelines for Merkel Cell Carcinoma (MCC) provide recommendations for diagnostic workup, clinical stage, and treatment options for patients. The panel meets annually to discuss updates to the guidelines based on comments from expert review from panel members, institutional review, as well as submissions from within NCCN and external organizations. These NCCN Guidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled "Clinical N0 Disease, Locally Advanced MCC." This new algorithm page addresses locally advanced disease, and the panel clarifies the meaning behind the term "nonsurgical" by further defining locally advanced disease. In addition, the guideline includes the management of in-transit disease and updates to the systemic therapy options.

摘要

NCCN Merkel 癌(MCC)指南为患者提供了诊断性检查、临床分期和治疗方案的建议。该专家组每年开会讨论根据专家组、机构审查以及 NCCN 内部和外部组织的意见对指南的更新。这些 NCCN 指南见解侧重于在临床淋巴结阴性状态下为局部晚期疾病引入一个新页面,标题为“临床 N0 疾病,局部晚期 MCC”。这个新的算法页面解决了局部晚期疾病问题,专家组通过进一步定义局部晚期疾病来澄清“非手术”这一术语的含义。此外,该指南还包括了转移疾病的治疗和系统治疗方案的更新。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验